PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vesting of the new employees' equity awards is subject to continued service through the applicable vesting dates.

Rhea-AI Summary

PTC Therapeutics (PTCT) approved equity compensation awards for 13 new employees on October 28, 2026, under Nasdaq's inducement grant exception.

The awards include non-statutory stock options and 11,535 restricted stock units, each representing the right to receive one common share upon vesting. The options have an exercise price of $63.02 per share, equal to the closing share price on the grant date, and a 10-year term. Both award types vest over four years. The Compensation Committee approved the grants as an inducement material to the employees' acceptance of employment.

Positive

• None.

Negative

• Minor point. Forward-looking: it has not happened yet and may not happen.11,535 restricted stock units create potential dilution as employees vest and receive common shares.
• Minor point. Forward-looking: it has not happened yet and may not happen.Stock options exercisable at $63.02 per share create potential dilution upon exercise.

Key Figures

New employees: 13 employees Stock options: 9.620 shares Restricted stock units: 11,535 RSUs +3 more

New employees

13 employees

Recipients of the inducement awards

Stock options

9.620 shares

Aggregate shares underlying the options

Restricted stock units

11,535 RSUs

Each RSU represents one share upon vesting

Option exercise price

$63.02 per share

Closing share price on the grant date

Option term

10 years

Term of each stock option award

Award vesting period

4 years

Stock options and RSUs, subject to continued service

Historical Context

1 past event · Latest: Sep 25

1 event

1. Sep 25

   Inducement grants

   24h Move

   +5.2%

   Prior inducement award covered 37 hires with 51,270 options and 37,995 RSUs at $65.96.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

non-statutory stock options, restricted stock units, nasdaq listing rule 5635(c)(4)

3 terms

non-statutory stock options financial

"approved non-statutory stock options to purchase an aggregate of 9.620 shares"

Non-statutory stock options are a type of reward that companies give to employees, allowing them to buy company shares at a set price within a certain period. Unlike formal or government-approved plans, these options are more flexible but may have different tax implications. For investors, they can influence a company's stock price and financial health, making them an important factor to consider.

restricted stock units financial

"and 11,535 restricted stock units ("RSUs"), each representing the right"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WARREN, N.J., Oct. 30, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Oct. 28, 2026, the company approved non-statutory stock options to purchase an aggregate of 9.620 shares of its common stock and 11,535 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 13 new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires' employment compensation.

The inducement grants were approved by PTC's Compensation Committee on Oct. 28, 2026, and are being made as an inducement material to each employee's acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).

All stock option awards have an exercise price of $63.02 per share, the closing price of PTC's common stock on Oct. 28, 2026, the date of the grant. The stock options each have a 10-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee's new hire date and 6.25% of the original number of shares vesting at the end of each subsequent three-month period thereafter until fully vested, subject to the employee's continued service with the company through the applicable vesting dates. The RSUs each will vest over four years with 25% of the original number of shares vesting on each annual anniversary of the applicable employee's new hire date until fully vested, subject to the employee's continued service with the company through the applicable vesting dates.

About PTC Therapeutics, Inc. 
PTC is a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company's strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders. To learn more about PTC, please visit www.ptcbio.com and follow on LinkedIn, X, Facebook and Instagram.

For more information please contact:

Investors:
Ellen Cavaleri
+1 (615) 618-6228
ecavaleri@ptcbio.com

Media:
Jeanine Clemente
+1 (908) 912-9406
jclemente@ptcbio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302925016.html

SOURCE PTC Therapeutics, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did PTC Therapeutics approve for new employees on October 28, 2026?

PTC Therapeutics approved non-statutory stock options and 11,535 restricted stock units for 13 new employees. The options carry a $63.02 exercise price and a 10-year term. The awards were approved under Nasdaq Listing Rule 5635(c)(4) as employment inducements.

How do PTC Therapeutics' October 2026 inducement awards vest?

The options and restricted stock units vest over four years, subject to continued service through each applicable vesting date. Options vest 25% on the first anniversary of the employee's new hire date, then 6.25% at the end of each subsequent three-month period. Restricted stock units vest 25% on each annual anniversary of the new hire date.